Pharma body to cap prices of cigarette substitutes, seeks data

NEW DELHI:  National Pharmaceutical Pricing Authority (NPPA) has sought data on price to retailers and annual turnover from all companies involved in the manufacturing of nicotine replacement therapies (NRTs).

Officials said this will be used to fix the ceiling price of these products which help people quit smoking or chewing tobacco. NRTs, which come in different forms such as mouth dissolving strips, tablets, and oral inhalers, provide a controlled amount of nicotine to help reduce cravings and withdrawal symptoms.

The data has been sought from manufacturers and marketing firms on NRTs containing nicotine in 2 mg and 4 mg strengths (about half the weight of a grain of table salt).

“The information may be furnished positively within seven days from the issue of this OM (office memorandum) for taking appropriate action for fixation of ceiling prices pursuant to the issue of the Revised Schedule-I of DPCO, 2013,” said the authority in the OM issued with a copy to apex pharma associations, including IDMA, IPA, OPPI, FOPE, FICCI, ASSOCHAM, among others for information and necessary action.

NRT formulations were included in the National List of Essential Medicine (NLEM), 2022, for the first time and with the revision of Schedule-I of the Drugs Prices Control Order (DPCO), 2013, along with the NLEM, these formulations were added to the schedule’s list.

Related Posts

  • Pharma
  • February 17, 2025
  • 64 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 62 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%